文献速递泌尿男性生殖肿瘤

免疫检查点抑制剂时代转移性透明细胞肾细胞癌新预后模型的开发与外部验证

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.
PubMed 文献 · Lancet Oncol · 2026-09-09

本研究利用CheckMate-214和CheckMate-9ER试验的个体患者数据,开发并外部验证了CPI2预后模型,并验证了IMDC模型。校准显示预测与观察死亡风险一致性良好,PD-L1表达未提高预后准确性。

要点

  • CPI2模型基于14个常规临床参数,区分准确度优于IMDC模型。
  • PD-L1表达未改善CPI2模型的预后准确性。

核心结论

  • CPI2模型使用14个易获取的临床参数,与IMDC模型相比提高了区分准确度。
  • 该分类需在其他试验和观察人群进一步验证,并用于重新分析免疫检查点抑制剂联合方案的疗效异质性。

研究设计与样本

  • 研究使用CheckMate-214和CheckMate-9ER临床试验的个体患者数据,分别用于CPI2模型的开发和外部验证。
  • 两项试验纳入既往未治疗的mccRCC患者,所有IMDC预后组,Karnofsky体能状态至少70%,随机接受舒尼替尼或纳武利尤单抗联合伊匹木单抗(CheckMate-214)或纳武利尤单抗联合卡博替尼(CheckMate-9ER)。
  • 使用Cox比例风险模型,基于Akaike信息准则向后选择预测因子,采用Bootstrapping估计系数和收缩因子校正乐观度。

主要发现

  • CheckMate-214纳入1096例患者(2014年10月至2016年2月),CheckMate-9ER纳入651例患者(2017年9月至2019年5月)。
  • CheckMate-214中位随访40个月(IQR 13-94),CheckMate-9ER中位随访38个月(IQR 15-53)。
  • 1747例患者中665例(38%)年龄65岁及以上,1289例(74%)男性,458例(26%)女性。
  • CPI2模型基于年龄、Karnofsky体能状态、既往肾切除术、转移部位(肝、肺、骨和淋巴结)及七个实验室参数(钙、碱性磷酸酶、白蛋白、乳酸脱氢酶、中性粒细胞绝对计数、淋巴细胞计数和白细胞计数)开发。

关键数值与推荐

  • CPI2模型包含14个参数:年龄、Karnofsky体能状态、既往肾切除术、转移部位(肝、肺、骨、淋巴结)及七个实验室参数(钙、碱性磷酸酶、白蛋白、乳酸脱氢酶、中性粒细胞绝对计数、淋巴细胞计数、白细胞计数)。

临床怎么用

  • CPI2模型可用于mccRCC患者的预后分层,辅助临床试验设计和治疗决策。
  • 该模型基于常规临床参数,易于在临床实践中应用。
  • 建议在其他试验和观察人群中进一步验证CPI2模型。

局限性

  • 研究仅基于两项临床试验数据,需在更广泛人群中验证。
  • 未报告其他潜在预后因素或生物标志物的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prognostic classification of patients with metastatic clear cell renal cell carcinoma (mccRCC) is instrumental for clinical trials and treatment decisions. Hence, optimal performance of prognostic models is crucial. This study aimed to develop and externally validate the new Clinical Prognostic Index in the Checkpoint Inhibitor era (CPI2) model using clinical trial data, and to externally validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. METHODS: Individual patient data from the clinical trials CheckMate-214 and CheckMate-9ER were used for development and external validation of the CPI2 model, respectively. Both trials included previously untreated mccRCC patients of all IMDC prognostic groups and Karnofsky performance status of at least 70%, and randomly allocated them to receive either sunitinib or nivolumab plus ipilimumab (CheckMate-214) or nivolumab plus cabozantinib (CheckMate-9ER). Using a Cox proportional hazards model, predictors were selected from a list of patient, disease, and laboratory parameters using Akaike information criterion-based backwards selection. Bootstrapping was used to estimate coefficients and a shrinkage factor to correct for optimism. Calibration plots and Uno's C-index for discriminative accuracy were calculated for the CPI2 model and IMDC model in both trial populations. FINDINGS: Data from 1096 patients included in CheckMate-214 between October, 2014, and February, 2016, and 651 patients included in CheckMate-9ER between September, 2017, and May, 2019, were used. Median follow-up was 40 months (IQR 13-94) in CheckMate-214 data and 38 months (15-53) in CheckMate-9ER data. In total, 665 (38%) of 1747 patients were aged 65 years or older; 1289 (74%) were male, and 458 (26%) were female. A prognostic model based on age, Karnofsky performance status, previous nephrectomy, metastatic locations (liver, lung, bone, and lymph node), and seven laboratory parameters (calcium, alkaline phosphatase, albumin, lactate dehydrogenase, absolute neutrophil count, lymphocyte count, and white blood cell count) was developed based on CheckMate-214 data. Classification into three prognostic groups provided discriminative accuracy at 36 months of 0·72 (95% CI 0·69-0·75) in CheckMate-214 and 0·72 (0·68-0·76) in CheckMate-9ER, which was 0·65 (0·62-0·68) and 0·61 (0·57-0·65) for the IMDC classification, respectively. Calibration showed adequate agreement between predicted and observed mortality risks. PD-L1 expression did not improve prognostic accuracy. CPI2 favourable, intermediate, and poor risk groups included 472 (43%), 366 (33%), and 258 (24%) of 1096 CheckMate-214 patients and 257 (39%), 196 (30%), and 198 (30%) of 651 CheckMate-9ER patients, respectively. INTERPRETATION: The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape. FUNDING: Josephine Nefkens Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Richters A, Bond MJG, Westgeest HM, et al. Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era. Lancet Oncol. 2026. PMID: 42716079. doi:10.1016/S1470-2045(26)00338-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。